Literature DB >> 35005084

TGIRT-seq Protocol for the Comprehensive Profiling of Coding and Non-coding RNA Biotypes in Cellular, Extracellular Vesicle, and Plasma RNAs.

Hengyi Xu1, Ryan M Nottingham1, Alan M Lambowitz1.   

Abstract

High-throughput RNA sequencing (RNA-seq) has extraordinarily advanced our understanding of gene expression and disease etiology, and is a powerful tool for the identification of biomarkers in a wide range of organisms. However, most RNA-seq methods rely on retroviral reverse transcriptases (RTs), enzymes that have inherently low fidelity and processivity, to convert RNAs into cDNAs for sequencing. Here, we describe an RNA-seq protocol using Thermostable Group II Intron Reverse Transcriptases (TGIRTs), which have high fidelity, processivity, and strand-displacement activity, as well as a proficient template-switching activity that enables efficient and seamless RNA-seq adapter addition. By combining these activities, TGIRT-seq enables the simultaneous profiling of all RNA biotypes from small amounts of starting material, with superior RNA-seq metrics, and unprecedented ability to sequence structured RNAs. The TGIRT-seq protocol for Illumina sequencing consists of three steps: (i) addition of a 3' RNA-seq adapter, coupled to the initiation of cDNA synthesis at the 3' end of a target RNA, via template switching from a synthetic adapter RNA/DNA starter duplex; (ii) addition of a 5' RNA-seq adapter, by using thermostable 5' App DNA/RNA ligase to ligate an adapter oligonucleotide to the 3' end of the completed cDNA; (iii) minimal PCR amplification, to add capture sites and indices for Illumina sequencing. TGIRT-seq for the Illumina sequencing platform has been used for comprehensive profiling of coding and non-coding RNAs in ribodepleted, chemically fragmented cellular RNAs, and for the analysis of intact (non-chemically fragmented) cellular, extracellular vesicle (EV), and plasma RNAs, where it yields continuous full-length end-to-end sequences of structured small non-coding RNAs (sncRNAs), including tRNAs, snoRNAs, snRNAs, pre-miRNAs, and full-length excised linear intron (FLEXI) RNAs. Graphic abstract: Figure 1.Overview of the TGIRT-seq protocol for Illumina sequencing.Major steps are: (1) Template switching from a synthetic R2 RNA/R2R DNA starter duplex with a 1-nt 3' DNA overhang (a mixture of A, C, G, and T residues, denoted N) that base pairs to the 3' nucleotide of a target RNA, and upon initiating reverse transcription by adding dNTPs, seamlessly links an R2R adapter to the 5' end of the resulting cDNA; (2) Ligation of an R1R adapter to the 3' end of the completed cDNA; and (3) Minimal PCR amplification with primers that add Illumina capture sites (P5 and P7) and barcode sequences (indices 5 and 7). The index 7 barcode is required, while the index 5 barcode is optional, to provide unique dual indices (UDIs).
Copyright © 2021 The Authors; exclusive licensee Bio-protocol LLC.

Entities:  

Keywords:  Group II intron reverse transcriptase; Illumina sequencing; Non-LTR-retroelement; RNA-seq; Reverse transcriptase; Template switching; Transcriptomics

Year:  2021        PMID: 35005084      PMCID: PMC8678547          DOI: 10.21769/BioProtoc.4239

Source DB:  PubMed          Journal:  Bio Protoc        ISSN: 2331-8325


  42 in total

1.  Domain structure and three-dimensional model of a group II intron-encoded reverse transcriptase.

Authors:  Forrest J H Blocker; Georg Mohr; Lori H Conlan; Li Qi; Marlene Belfort; Alan M Lambowitz
Journal:  RNA       Date:  2004-12-01       Impact factor: 4.942

2.  Smart-seq2 for sensitive full-length transcriptome profiling in single cells.

Authors:  Simone Picelli; Åsa K Björklund; Omid R Faridani; Sven Sagasser; Gösta Winberg; Rickard Sandberg
Journal:  Nat Methods       Date:  2013-09-22       Impact factor: 28.547

3.  Reverse transcriptase template switching: a SMART approach for full-length cDNA library construction.

Authors:  Y Y Zhu; E M Machleder; A Chenchik; R Li; P D Siebert
Journal:  Biotechniques       Date:  2001-04       Impact factor: 1.993

4.  Widespread Influence of 3'-End Structures on Mammalian mRNA Processing and Stability.

Authors:  Xuebing Wu; David P Bartel
Journal:  Cell       Date:  2017-05-18       Impact factor: 41.582

5.  Protein synthesis. Rqc2p and 60S ribosomal subunits mediate mRNA-independent elongation of nascent chains.

Authors:  Peter S Shen; Joseph Park; Yidan Qin; Xueming Li; Krishna Parsawar; Matthew H Larson; James Cox; Yifan Cheng; Alan M Lambowitz; Jonathan S Weissman; Onn Brandman; Adam Frost
Journal:  Science       Date:  2015-01-02       Impact factor: 47.728

6.  Origin and evolution of retroelements based upon their reverse transcriptase sequences.

Authors:  Y Xiong; T H Eickbush
Journal:  EMBO J       Date:  1990-10       Impact factor: 11.598

7.  RNA-seq of human reference RNA samples using a thermostable group II intron reverse transcriptase.

Authors:  Ryan M Nottingham; Douglas C Wu; Yidan Qin; Jun Yao; Scott Hunicke-Smith; Alan M Lambowitz
Journal:  RNA       Date:  2016-01-29       Impact factor: 4.942

8.  Reducing the structure bias of RNA-Seq reveals a large number of non-annotated non-coding RNA.

Authors:  Vincent Boivin; Gaspard Reulet; Olivier Boisvert; Sonia Couture; Sherif Abou Elela; Michelle S Scott
Journal:  Nucleic Acids Res       Date:  2020-03-18       Impact factor: 16.971

9.  High-resolution quantitative profiling of tRNA abundance and modification status in eukaryotes by mim-tRNAseq.

Authors:  Andrew Behrens; Geraldine Rodschinka; Danny D Nedialkova
Journal:  Mol Cell       Date:  2021-02-12       Impact factor: 17.970

10.  Efficient and quantitative high-throughput tRNA sequencing.

Authors:  Guanqun Zheng; Yidan Qin; Wesley C Clark; Qing Dai; Chengqi Yi; Chuan He; Alan M Lambowitz; Tao Pan
Journal:  Nat Methods       Date:  2015-07-27       Impact factor: 28.547

View more
  1 in total

1.  Group II intron-like reverse transcriptases function in double-strand break repair.

Authors:  Seung Kuk Park; Georg Mohr; Jun Yao; Rick Russell; Alan M Lambowitz
Journal:  Cell       Date:  2022-09-15       Impact factor: 66.850

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.